Literature DB >> 19082529

Successful treatment of refractory polymyositis with the immunosuppressant mizoribine: case report.

A Suwa1, M Hirakata, Y Kaneko, S Sato, Y Suzuki, M Kuwana.   

Abstract

We describe a patient who presented with polymyositis with anti-Jo-1 antibodies at 18 years after the onset of rheumatoid arthritis and was successfully treated with the immunosuppressive drug mizoribine at the time of exacerbation. She had developed diabetes mellitus, cerebral infarction, and myocardial infarction after high-dose steroid therapy was initiated. Therefore, an immunosuppressant was preferred as the second-line agent. Treatment with 150 mg/day of mizoribine and 8 mg/day of prednisolone resulted in eventual normalization of muscle enzyme levels. Mizoribine is a purine antimetabolite that inhibits T cell activation/proliferation and B cell proliferation. The potential efficacy of mizoribine for polymyositis was suggested by this case.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19082529     DOI: 10.1007/s10067-008-1050-6

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  14 in total

Review 1.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

2.  Tacrolimus in refractory polymyositis with interstitial lung disease.

Authors:  C V Oddis; F C Sciurba; K A Elmagd; T E Starzl
Journal:  Lancet       Date:  1999-05-22       Impact factor: 79.321

3.  Intravenous pulse cyclophosphamide therapy in myositis and Sjögren's syndrome.

Authors:  J P Leroy; A A Drosos; D I Yiannopoulos; P Youinou; H M Moutsopoulos
Journal:  Arthritis Rheum       Date:  1990-10

4.  Studies on bredinin. I. Isolation, characterization and biological properties.

Authors:  K Mizuno; M Tsujino; M Takada; M Hayashi; K Atsumi
Journal:  J Antibiot (Tokyo)       Date:  1974-10       Impact factor: 2.649

5.  Clinical trial of Bredinin in renal transplantation.

Authors:  T Inou; R Kusaba; I Takahashi; H Sugimoto; K Kuzuhara; Y Yamada; J Yamauchi; O Otsubo
Journal:  Transplant Proc       Date:  1980-09       Impact factor: 1.066

Review 6.  Cyclosporin A in the treatment of refractory adult polymyositis/dermatomyositis: population based experience in 6 patients and literature review.

Authors:  K A Qushmaq; A Chalmers; J M Esdaile
Journal:  J Rheumatol       Date:  2000-12       Impact factor: 4.666

Review 7.  Current concepts in the idiopathic inflammatory myopathies: polymyositis, dermatomyositis, and related disorders.

Authors:  P H Plotz; M Dalakas; R L Leff; L A Love; F W Miller; M E Cronin
Journal:  Ann Intern Med       Date:  1989-07-15       Impact factor: 25.391

Review 8.  Treatment of idiopathic inflammatory myopathies.

Authors:  Anthony A Amato; Robert C Griggs
Journal:  Curr Opin Neurol       Date:  2003-10       Impact factor: 5.710

9.  Prednisone and azathioprine for polymyositis: long-term followup.

Authors:  T W Bunch
Journal:  Arthritis Rheum       Date:  1981-01

10.  Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy.

Authors:  M M Joffe; L A Love; R L Leff; D D Fraser; I N Targoff; J E Hicks; P H Plotz; F W Miller
Journal:  Am J Med       Date:  1993-04       Impact factor: 4.965

View more
  2 in total

1.  Novel approaches in the treatment of myositis and myopathies.

Authors:  Jemima Albayda; Lisa Christopher-Stine
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-10       Impact factor: 5.346

2.  Stroke and Stroke-like Episodes in Muscle Disease.

Authors:  Josef Finsterer
Journal:  Open Neurol J       Date:  2012-05-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.